Alnylam Pharmaceuticals
Data Breaches, Cyber Attacks and Security Report

https://alnylam.com  ᛫  Biotech & Pharmaceuticals
Last updated September 21, 2019

About Alnylam Pharmaceuticals

Company Overview

Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Valuation

Employees

CEO

John M. Maraganore

Location

Data Breaches and Security News

Alnylam Pharmaceuticals Security Rating

Sorry, this security report couldn't be loaded at this time. Please try again later.

UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Alnylam Pharmaceuticals is implementing good security practices.

Passed Checks

Passed{{ passedCheck.passTitle }}

Failed Checks

Warning{{ failedCheck.failTitle }}

View a free security report for Alnylam Pharmaceuticals

Get full security report ›

Related posts

Read more about the latest issues in cybersecurity

More security reports

Compare Alnylam Pharmaceuticals's security performance with other companies